alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. [electronic resource]
Producer: 20051115Description: 217-26 p. digitalISSN:- 0269-2813
- Aged
- Angiogenesis Inhibitors -- therapeutic use
- Biomarkers, Tumor -- blood
- Carcinoma, Hepatocellular -- blood
- Disease-Free Survival
- Female
- Humans
- Liver Neoplasms -- blood
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Severity of Illness Index
- Survival Analysis
- Thalidomide -- therapeutic use
- Treatment Outcome
- alpha-Fetoproteins -- metabolism
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.